INOVIO Reports Fourth Quarter 2021 and Year-End Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Inovio Pharmaceuticals (INO) PT Lowered to $30 at Oppenheimer
March 2, 2022 12:56 PM ESTOppenheimer analyst Hartaj Singh lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $30.00 (from $35.00) while maintaining an Outperform rating after the company provided a business and pipeline update to investors on 3/1.
The analyst commented, "While the company reported steady progress, the... More
Inovio Pharma (INO) Misses Q4 EPS by $1.13
March 1, 2022 4:33 PM ESTInovio Pharma (NASDAQ: INO) reported Q4 EPS of ($1.45), $1.13 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $1.77 million versus the consensus estimate of $2.84 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
... More